EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Expert Consensus on Cytomegalovirus Management in Recipients of CAR‐T Cell and Bispecific Antibody Therapies

Wenyue Cao, Fankai Meng, Sizhou Feng, Mingfeng Zhao, Jianxin Song, Yuqian Sun, Weijie Cao, Weiwei Tian, Yongxian Hu, Fangyi Fan, Xiaowen Tang, Wenbin Qian, Yicheng Zhang, Jia Wei

Journal of Evidence-Based Medicine · 2026-03 · 19 (1)

DOI: 10.1111/jebm.70107 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Cytomegalovirus (CMV) is an increasingly recognized complication of chimeric antigen receptor T‐cell (CAR‐T) and bispecific antibody (BsAb) therapies for hematologic malignancies, driven by therapy‐related immunosuppression and cumulative exposure to lymphodepleting or steroid regimens. Given China's high adult CMV IgG seroprevalence (>90%), baseline risk, interpretation of low‐level DNAemia, and operational thresholds differ from low‐seroprevalence settings, requiring context‐specific guidance. This China‐adapted, evidence‐graded consensus was developed by a multidisciplinary panel from major centers using a modified Delphi process and Oxford Centre for Evidence‐Based Medicine levels to translate international guidance into a high‐seroprevalence setting. Recommendations prioritize early risk stratification and pragmatic surveillance. We advise routine CMV monitoring by real‐time quantitative PCR during the first 30 days after therapy, with risk‐adapted extension thereafter. Interpretation and treatment triggers are anchored to WHO‐traceable IU/mL and specified by specimen matrix to support comparability across assays. Consideration of prophylaxis is proposed for well‐defined high‐risk subgroups, acknowledging the need for prospective validation. Syndrome‐based diagnostic and treatment algorithms are provided for tissue‐invasive disease, including CMV pneumonia and encephalitis, with guidance on antiviral induction, step‐down, and monitoring for virologic response and drug toxicity. This consensus explicitly adapts international recommendations to China's epidemiology, assay practice, and drug accessibility. By standardizing prevention, surveillance, and management in CAR T‐cell and BsAb recipients, this consensus aims to lower non‐relapse mortality and improve long‐term outcomes. Priority research needs include harmonized viral‐load thresholds, validation of risk‐adapted prophylaxis strategies, and studies that clarify the significance of low‐level DNAemia in this population.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →